Background：Oxelumab is a human monoclonal antibody designed for the treatment of autoimmune diseases.3 Oxelumab recognizes human OX40L TNFSF4. OX40L is a member of the tumor necrosis family and is the ligand for OX40 . The OX40/OX40L interaction generates an optimal T cell response and plays a significant role in determining the amount of memory T-cells remaining after the immune response.1 Therapeutic treatments with antibodies against TNFSF can sometimes result in serious side effects.2 More research is needed to understand the precise molecular mechanism of TNF inhibition. This cost-effective, research-grade Anti-Human OX40L Oxelumab utilizes the same variable regions from the therapeutic antibody Oxelumab making it ideal for research projects.
Alternative Names：R4930, RG4930, RO4989991, huMAb OX40L,,
